https://sputnikglobe.com/20211121/gamaleya-russian-covid-19-treatment-drug-may-get-approval-by-end-of-2022-1090906799.html

Gamaleya: Russian COVID-19 Treatment Drug May Get Approval By End of 2022

Sputnik International

MOSCOW (Sputnik) - The Russian Gamaleya research center has developed the chemical compounds to create a drug to treat COVID-19 and expects to get it approved... 21.11.2021, Sputnik International

2021-11-21T17:31+0000

2021-11-21T18:30+0000

covid-19

https://cdn1.img.sputnikglobe.com/img/107835/51/1078355126_0:40:1281:760_1920x0_80_0_0_a0acfdaa11fc60d6b1f715d78add565c.jpg

Another COVID-19 drug, based on monoclonal antibodies as the one used to treat former US President Donald Trump, is nearly ready and can be expected to be registered within the next three-five months, Logunov said at a meeting with Russian President Vladimir Putin. The treatment has proved to be 100% effective against COVID-19 in animal trials and is now entering the clinical trial stage on volunteers, he added.The development of the chemical drug, on the other hand, is still at an early stage and trials on animals are required, Logunov said.Creating COVID-19 treatment drug takes more time than creating a drug based on monoclonal antibodies, Logunov added. He expressed hope that the drug will be registered by the end of 2022 after successful animal and clinical trials.

Sputnik International

feedback@sputniknews.com

+74956456601

MIA „Rossiya Segodnya“

252

2021

Sputnik International

feedback@sputniknews.com

+74956456601

MIA „Rossiya Segodnya“

252

News

en_EN

Sputnik International

feedback@sputniknews.com

+74956456601

MIA „Rossiya Segodnya“

252

1920

1080

true

1920

1440

true

https://cdn1.img.sputnikglobe.com/img/107835/51/1078355126_106:0:1173:800_1920x0_80_0_0_eb7abb056dbdc627ecc1d0b388c73cd4.jpg

1920

true

Sputnik International

feedback@sputniknews.com

+74956456601

MIA „Rossiya Segodnya“

252

Sputnik International

covid-19

Gamaleya: Russian COVID-19 Treatment Drug May Get Approval By End of 2022

17:31 GMT 21.11.2021 (Updated: 18:30 GMT 21.11.2021)

© CDCThis illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses. Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding the virion, when viewed electron microscopically. A novel coronavirus, named Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China in 2019. The illness caused by this virus has been named coronavirus disease 2019 (COVID-19).

This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses. Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding the virion, when viewed electron microscopically. A novel coronavirus, named Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China in 2019. The illness caused by this virus has been named coronavirus disease 2019 (COVID-19). - Sputnik International, 1920, 21.11.2021

MOSCOW (Sputnik) - The Russian Gamaleya research center has developed the chemical compounds to create a drug to treat COVID-19 and expects to get it approved by the end of next year after clinical trials, Denis Logunov, the center's deputy head, said on Sunday.

Another COVID-19 drug, based on monoclonal antibodies as the one used to treat former US President Donald Trump, is nearly ready and can be expected to be registered within the next three-five months, Logunov said at a meeting with Russian President Vladimir Putin. The treatment has proved to be 100% effective against COVID-19 in animal trials and is now entering the clinical trial stage on volunteers, he added.

The development of the chemical drug, on the other hand, is still at an early stage and trials on animals are required, Logunov said.

"At the moment we have carried out an initial screening, and we have compounds... that are hits, leading compounds that will be optimized and tested in experiments on animals," Logunov explained.

Creating COVID-19 treatment drug takes more time than creating a drug based on monoclonal antibodies, Logunov added. He expressed hope that the drug will be registered by the end of 2022 after successful animal and clinical trials.

COVID-19